@article{3104358,
    title = "Reactivating ovarian function through autologous platelet-rich plasma intraovarian infusion: Pilot data on premature ovarian insufficiency, perimenopausal, menopausal, and poor responder women",
    author = "Sfakianoudis, K. and Simopoulou, M. and Grigoriadis, S. and Pantou, A. and Tsioulou, P. and Maziotis, E. and Rapani, A. and Giannelou, P. and Nitsos, N. and Kokkali, G. and Koutsilieris, M. and Pantos, K.",
    journal = "Journal of Clinical Medicine Research",
    year = "2020",
    volume = "9",
    number = "6",
    pages = "1-25",
    publisher = "MDPI",
    issn = "1918-3003, 1918-3011",
    doi = "10.3390/jcm9061809",
    keywords = "Muellerian inhibiting factor, adult;  antral follicle count;  Article;  body mass;  embryo transfer;  female;  hormone substitution;  human;  major clinical study;  menopausal syndrome;  menopause;  menstruation disorder;  middle aged;  oocyte development;  outcome assessment;  ovary function;  ovary insufficiency;  pathophysiology;  pilot study;  prematurity;  thrombocyte rich plasma",
    abstract = "Intraovarian platelet-rich plasma (PRP) infusion was recently introduced in the context of addressing ovarian insufficiency. Reporting on its effectiveness prior to adopting in clinical routine practice is imperative. This study aims to provide pilot data regarding PRP application for ovarian rejuvenation. Four pilot studies were conducted on poor ovarian response (POR), premature ovarian insufficiency (POI), perimenopause, and menopause, respectively. Each pilot study reports on thirty patients, 120 participants were recruited in total. All participants provided written informed consent prior to treatment. Primary outcome measures for the POR pilot study were levels of anti-müllerian hormone (AMH), antral follicle count (AFC) and oocyte yield. For the POI, perimenopausal and menopausal pilot studies primary outcome measures were restoration of menstrual cycle, and Follicle Stimulating Hormone (FSH) levels. A significant improvement on the hormonal profile and the ovarian reserve status was noted, along with improved intracytoplasmic sperm injection (ICSI) cycle performance concerning POR participants. Menstruation recovery was observed in 18 out of 30 POI patients, along with a statistically significant improvement on levels of AMH, FSH, and AFC. Similarly, 13 out of 30 menopausal women positively responded to PRP treatment. Finally, menstruation regularity, improved hormonal levels and AFC were reported for 24 out of 30 perimenopausal women. To conclude, PRP infusion appears to convey promising results in addressing ovarian insufficiency. © 2020 by the authors. Licensee MDPI, Basel, Switzerland."
}